Clinical Trial

Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria

Study acronym: Phase III
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2025 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study was to evaluate the efficacy and safety of cetirizine hydrochloride injection in the treatment of acute urticaria.The participants were randomized to receive cetirizine hydrochloride or diphenhydramine hydrochloride.
Trial Details
NCT Number NCT06819774
Lead Sponsor Shandong New Time Pharmaceutical Co., LTD
Conditions Acute Urticaria
Enrollment 284 participants
Start Date 2024-04-22
Primary Completion 2025-08 (estimated)
Study Completion 2025-08 (estimated)
Updated on ClinicalTrials.gov 2025-02-11